We are pleased to announce that Ontario Drug Benefit (ODB) has listed Afinitor (everolimus) for the treatment of patients with GI/Lung NET, effective November 20, 2017 through the Exceptional Access Program (EAP) with the following criteria:
Afinitor (everolimus): The Patient:
ODB FORMULARY – EDITION NO. 42, Summary of Changes – November 2017
Summary of Changes – November 2017 to Edition No. 42 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective November 30, 2017. The updated Edition No. 42 document will be posted on the Ministry’s website http://www.health.gov.on.ca/en/pro/programs/drugs/edition_42.aspx by November 30, 2017.
Exceptional Access Program (EAP) Product
Afinitor (everolimus) 2.5mg, 5mg, 7.5mg, 10mg Tab (NOV) – Effective Date: November 20, 2017
For the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) according to clinical criteria. The 7.5mg Tab is also a newly funded strength.